Innovation Digest – September 2021 Vol. 1

We’re choking on data but lack agreement on what data is important – to the patient, to clinical and quality of life outcomes, to society. We know intuitively that prevention is essential, and yet, when we don’t agree on or incentivize its value, the cost is astronomical. COVID is providing us a graphic example, but the ongoing epidemics of mental health and substance use are another alarming waste of dollars and lives. The demand for robust innovation and for simultaneous cost saving implies that we merely have a problem of tension in the business of health care that should be rectified with government policy and regulation. In reality, we are missing the vital opportunity to define and measure what is important to improve our society’s health. Complexity, scientific rigor, and legal barriers must not slow our relentless pursuit of understanding the experience, health goals and outcomes of diverse patient communities. Their expertise is perhaps the most important element in realigning our research, care delivery and financing systems toward actual health.

In this issue:

  • Racism in Medicine Is Alive and Well
  • Innovation At The Centers For Medicare And Medicaid Services: A Vision For The Next 10 Years
  • Apple Aims to Push More Patient Data to Doctors. But Who Can Gauge Its Impact on Health?
  • Private Equity and Health Care Delivery
  • More than 50 long-term effects of COVID-19: a systematic review and meta-analysis
  • KFF: Preventable COVID hospitalizations among unvaccinated cost U.S. health system $2.3B
  • Clinical Trials In Crisis: Building On COVID-19’s Lessons Toward A Better Future
  • ‘Reentry’ after cancer treatment offers lessons for emerging from the pandemic


Back to Viewpoint